Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jun;57(6):735-41.
doi: 10.1111/j.1365-2125.2004.02077.x.

Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis

T Trenque  1 , N Simon, I Villena, C Chemla, C Quereux, B Leroux, R Jaussaud, G Rémy, D Dupouy, H Millart, J-M Pinon, S Urien
Affiliations

Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis

T Trenque et al. Br J Clin Pharmacol. 2004 Jun.

Abstract

Aims: To develop a population pharmacokinetic model for pyrimethamine (PYR) and sulfadoxine (SDX) in children with congenital toxoplasmosis.

Methods: Children were treated with PYR (1.25 mg kg(-1)) and SDX (25 mg kg(-1)) (Fansidar) plus folinic acid (Lederfoline) 5 mg). Plasma concentrations, available from a therapeutic drug monitoring database, were determined by high-performance liquid chromatography. Population pharmacokinetic analysis was performed using a nonlinear mixed effects model.

Results: Eighty-nine children, aged 1 week to 14 years and weighing 2.9-59 kg, were available for evaluation. Both PYR and SDX concentration-time profiles were best described by a one-compartment open model. Volume of plasma distribution (V) and clearance (CL) were significantly related to body weight (BW) using an allometric function. Typical CL and V estimates (95% confidence interval), for a child weighing 11 kg were 5.50 (5.28, 5.73) l day(-1) and 36 (33, 39) l for PYR and 0.26 (0.25, 0.27) l day(-1) and 2.1 (1.9, 2.3) l for SDX. For BW between 3.5 and 60 kg, plasma half-lives were predicted to vary from 4.0 to 5.2 days for PYR, and from 5.0 to 7.5 days for SDX.

Conclusion: This study indicated that body weight influences PYR and SDX pharmacokinetics in children. To optimize PYR/SDX combination treatment in congenital toxoplasmosis, short dosing intervals in very young low-wight children are probably appropriate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Predicted (PRED) vs. observed (OBS) plasma pyrimethamine concentrations based on the basic, covariate-free, model (a) and the final pharmacokinetic model, including the effect of body weight on CL and V(b) (n = 89 children)
Figure 2
Figure 2
Predicted (PRED) vs. observed (OBS) plasma sulfadoxine concentrations based on the basic, covariate-free, model (a) and the final pharmacokinetic model, including the effect of body weight on CL and V(b) (n = 89 children)
Figure 3
Figure 3
Elimination half-lives of sulfadoxine (upper curve) and pyrimethamine (lower curve) as a function of body weight
See this image and copyright information in PMC

References

    1. Villena I, Aubert D, Leroux B, et al. Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997. Scand J Infect Dis. 1998;30:295–300. - PubMed
    1. Schoondermark-van de Ven E, Vree T, Melchers W, Camps W, Galama J. In vitro effects of sulfadiazine and its metabolites alone and in combination with pyrimethamine on toxoplasma gondii. Antimicrob Agents Chemother. 1995;39:763–5. - PMC - PubMed
    1. Koppe JG, Loewer-Sieger DH, De Roever-Bonnet H. Results of 20 years follow up of congenital toxoplasmosis. Lancet. 1986;1:254–6. - PubMed
    1. Guerina NG. Congenital infection with Toxoplasma gondii. Pediatr Ann. 1994;23:138–51. - PubMed
    1. Harris C, Salgo MP, Tanowitz HB, Wittner M. In vitro assessment of antimicrobial agents against Toxoplasma gondii. J Infect Dis. 1988;157:14–22. - PubMed